Speakers & Panels – 2015 Health & Life Sciences Conference

Friday, October 30, 2015

Keynote Speakers


Kevin Churchwell, MD, is Boston Children’s Hospital’s first Executive Vice President of Health Affairs and its Chief Operating Officer, responsible for leading clinical and operating functions across the enterprise. His innovative thinking, solid business acumen and superb clinical and academic leadership are key to his success working collaboratively with the clinicians, researchers and staff members to build upon Boston Children’s strong tradition of clinical excellence.

Churchwell joined Boston Children’s in 2013, after serving as CEO for Nemours/Alfred I. duPont Hospital for Children, in Wilmington, DE, overseeing all patient operations since 2010. He has been named one of the top 25 minority health care executives by Modern Healthcare, one of the Nashville Business Journal’s Health Care Heroes, and the American Diabetes Association’s Father of the Year. He has also been honored by the NAACP with their annual Image Award/Matthew Walker Healthcare Award, received the prestigious Trumpet Award, and been inducted into the Nashville Public Schools Hall of Fame for his work in outreach to public high schools.

A graduate of Massachusetts Institute of Technology and Vanderbilt Medical School in Nashville, Kevin is no stranger to Boston, or to Boston Children’s, where he completed his residency in Pediatrics and a clinical fellowship in Anesthesia and Critical Care. He also served as an Attending Physician in our Medical Surgical Intensive Care Unit for two years before returning to Vanderbilt Children’s Hospital where he ultimately became CEO.


Andrew Dreyfus is President and Chief Executive Officer for Blue Cross Blue Shield of Massachusetts, one of the largest independent, not-for-profit Blue Cross Blue Shield plans in the country. Founded by a group of civic leaders in 1937, BCBSMA now provides coverage to nearly 3 million members. Consistently recognized for standards of service excellence that are among the highest in the nation, Blue Cross Blue Shield of Massachusetts is the choice for health care consumers seeking reliable and high quality health care coverage.

Prior to being named CEO in September 2010, Andrew served as Executive Vice President of Health Care Services for Blue Cross, where he was responsible for the company’s health and wellness, performance measurement and improvement, and provider contracting divisions. He also led the company’s collaborative efforts to improve the quality and safety of health care in Massachusetts. As part of that work, Andrew served on the Commonwealth of Massachusetts’ Special Commission on the Health Care Payment System, a ten-member panel that recommended sweeping changes to the state’s health care payment system.

Andrew previously served as the first President of the Blue Cross Blue Shield of Massachusetts Foundation, which works to expand access to health care for Massachusetts residents. During his tenure, the Foundation awarded nearly $17 million in grants to community organizations and launched a series of policy initiatives, including the “Roadmap to Coverage”, which contributed to the successful passage of the state’s landmark 2006 Health Reform Law.

Andrew serves on the board of the Kenneth B. Schwartz Center, the Harvard Risk Management Foundation, the United Way of Massachusetts Bay and Merrimack Valley, and the Board of Advisors for the Brigham & Women’s Hospital Center for Surgery and Public Health.

Andrew’s previous professional experience includes serving as Executive Vice President of the Massachusetts Hospital Association (MHA) where he led the development of nationally recognized initiatives to expand access to coverage, and improve quality and patient safety. He also served as the Massachusetts Undersecretary of Consumer Affairs and Business Regulation, and as Director of Operations and Director of Communications in the Massachusetts Executive Office of Human Services.


Michael Phalen is Executive Vice President and President, Medical Surgery (MedSurg) for Boston Scientific and a member of its Executive Committee. In this role, he plans and executes Boston Scientific’s growth strategies for the Company’s Endoscopy, Urology/Women’s Health and Neuromodulation businesses. Phalen also oversees Boston Scientific operations in Canada and Latin America.

Prior to assuming his current position in January 2012, Phalen was President of Boston Scientific International. He was responsible for planning and executing Boston Scientific’s international growth strategy.

Phalen joined Boston Scientific in 1988 and held various management positions of increasing responsibilities including Territory Manager, Product Manager, Regional Sales Manager, Group Product Manager, Director of Marketing, Vice President of Global Marketing and Senior Vice President and President of the company’s Endoscopy division.

Before joining Boston Scientific, Phalen held management positions with MD Technology, Kendall Healthcare and Pennwalt Pharmaceuticals. He earned a B.S. in General Science from Villanova University and an M.B.A. from Fairleigh Dickinson University.


Birgit Schoeberl, Ph.D. has served as the Head of Discovery of Merrimack Pharmaceuticals since January 2015. Dr. Schoeberl served as the Senior Vice President of Research from January 2014 to January 2015, as the Vice President of Research from October 2009 to January 2014 and in various other research roles since she joined Merrimack in 2003. Prior to joining, she was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational models of signaling networks. Dr. Schoeberl holds a Ph.D. in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an M.S. in chemical engineering from the University of Karlsruhe in Germany.


Ido serves as the Chairman and CEO of American Well Corporation and oversees the company’s corporate strategy. Ido has a lengthy track record of successfully leading technology companies in the healthcare field. In 1996, together with Phyllis Gotlib, he co-founded iMDSoft, a provider of enterprise software that automates hospital critical care units. He grew the company into a market leader with a large multi-national install base in the U.S., Europe, and East Asia. In 2001, Ido joined CareKey Inc. as Chief Executive Officer and took the company through its acquisition by the TriZetto group. Ido served as TriZetto’s Chief Business Strategy Officer until his departure in the summer of 2006. Ido continues to serve as the chairman of iMDSoft’s scientific advisory board. Ido received his MD from the Sackler School of Medicine.


Peter L. Slavin, MD, has been the president of Massachusetts General Hospital since 2003. From 1999–2002, he served as chairman and chief executive officer of the Massachusetts General Physicians Organization, which included more than 1,700 physicians and employed nearly 1,000 of them.

From 1997–1999, Dr. Slavin served as president of Barnes-Jewish Hospital in St. Louis, MO. Before that, he did his training in internal medicine at Mass General from 1984–1987 and was senior vice president and chief medical officer from 1994–1997.

Dr. Slavin graduated from Harvard College in 1979, Harvard Medical School in 1984 and Harvard Business School in 1990.

Dr. Slavin teaches internal medicine and health care management at Harvard Medical School, where he is a professor of health care policy. He lectures widely on topics including quality and utilization management, the economics of teaching hospitals and the state of physician practices.

Terrier Talks


Aaron has 25 years of product development experience. Previously, he worked at Hewlett Packard’s medical products group and was responsible for the design of user interfaces for patient monitoring systems that remain the industry standard. He then spent a decade as a Product Development Consultant, designing life science products for clients including Dade-Behring, Insulet, and Respironics, as well as consumer products for Samsung, General Motors, and OXO. Aaron attended Carnegie Mellon University where he earned a B.S. degree in Computer Engineering.


Dr. Ostrovsky is a physician and social entrepreneur, creating disruptive technology to better health for vulnerable populations. He specializes in applying Lean Startup Thinking and Design Thinking to discovering social and commercial value of innovations in healthcare.

He has previously worked in health policy, global health, and clinical research.

His Specialties Include: Lean Startup Thinking, Design Thinking, Customer and Product Development, Quality Improvement, Home and Community-based Services, Readmission reduction, Care coordination, Mobile technology, Geriatrics, Pediatrics, Agile Development, Health system strengthening, Incubation at Academic Medical Centers, Fundraising

Dr. Ostrovsky is currently a Senior Resident in Pediatrics in the Urban Health and Advocacy Track of the Boston Children’s Hospital and Boston Medical Center Combined Residency Program affiliated with Harvard Medical School and theBoston University School of Medicine. He is also an entrepreneur, having co-founded Care at Hand nearly four years ago with a vision to empower elderly home care workers with mobile technology allowing them to keep better track of their patients and keep up to date with best practices. He is currently CEO of the company.


Janie Tremlett serves as Vecna’s VP of Domestic and International Business. Throughout her 25 years in health IT, Janie has been a recognized leader in translating organizational challenges into innovative and practical technology solutions. Responsible for more than 50 successful technology implementations, Janie has held numerous positions including Sr. VP & Chief Marketing Officer at Concordant, CIO/CTO at Commercialware and Commonwealth Financial Network, and Director of Information Delivery at Blue Cross/Blue Shield where she managed the development of one of the first practice management applications. She has also been a key contributor to the electronic insurance claims and EDI standards committees, MGH’s Internet Health Care Forum, and a number of national technology initiatives. Janie’s articles have been published in magazines such as CIO Week, Healthcare IT News, and Information Week, and speaks frequently at industry events. Janie holds a B.S. in Mathematics from Union College and a MBA from Syracuse.


Paul Carlile is a Professor of Management and Information Systems at the Questrom School of Business. His work focuses on how to drive innovation across disciplinary boundaries in the scientific and technology sectors. His work on open innovation has been used to improve outcomes in software, government and drug development. He is currently serving as the Senior Dean for Innovation at Questrom where he is responsible for driving change to create more value for students and employers in how we “do” business education at the School.

Lightning Round


Since 1992, Rich has worked with life science clients globally to introduce digital effectiveness solutions.After roles as hospital administrator in two New England health systems, Rich served for fourteen years as CEO of Pharmedica Holdings, LLC, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meetings planning company in 1992, until its sale in 2001.

After Pharmedica, he co-founded Exploria SPS, LLC, a division of Exploria, Inc. Exploria SPS became the market leader for business-rule controlled and compliant content management for life sciences companies and physicians. Rich’s introduction and subsequent influence over digital services globally led to his recognition in 2007, by PharmaVoice magazine as one of the top 100 most influential people in pharma.

Foreseeing the trends in that have impacted the changing influence dynamic of payors on healthcare, Rich incubated a new and disruptive concept meant to serve as the transaction-fed, new marketplace for healthcare. This led to the incorporation of RIMEDIO, Inc. in October 2012., RIMEDIO is intent on reshaping the dynamic of how healthcare interacts and transacts to achieve mutual stakeholder objectives.

In 2014, he also began serving an advisory role for Artaic Health to support commercial strategies to assess role of automated pill dispensing robotics in ensuring medication adherence. The company is supported by a NIH Small Business Innovation Research (SBIR) grants and a MassVenture grant totaling $1.8M to test prototype feasibility and commercial viability in integrated medicine centers. Under Rich’s direction, Artaic Health graduate of the HealthBox accelerator and is currently a finalist at MassChallenge.


James Fox currently manages Obz Design, a technology development firm focused on improving the capabilities of healthcare providers operating in resource-limited environments globally. Obz Design partners with medical organizations to address opportunities in medical devices and information management. With experience in both Africa and Latin America, James has a wealth of knowledge about medical device development and a first-hand understanding of how to succeed despite lean resources. Previously, James created solutions for infant apnea and a phototherapy blanket to treat jaundice. Now James and Obz Design are poised to take on anemia, which affects 2 billion people and causes 1 million deaths annually. James’s background is mechanical engineering and product development. Before Obz Design, he worked for GE Aviation on next generation jet engine technology.


Ed’s background spans both business and technology. Prior to joining GoodLux Technology, he developed bond trading algorithms at JPMorgan. He holds a Ph.D. in Applied Physics from Harvard, where he wrote a dissertation on novel methods of light emission and collection in semiconductors. He’s also the biggest Steelers fan in Patriots territory, but he usually keeps his Terrible Towel at home.


Experience: Currently working in project management for meQuilibrium, a rapidly growing startup. Prior experience includes 4+ years experience working in business intelligence and strategy.

Focus of Interests: Project management, competitive intelligence, data analytics, and technology strategy

Education: MS/MBA Candidate at Boston University Questrom School of Business with a concentration in business analysis and strategy – graduated with High Honors. BS in Business Administration from Skidmore College.


Elliot Swart studied computer science and electrical engineering at Yale University, though his computer science education began at the age of eight, programming in Logo. Elliot’s research background includes gene therapy work at the Khavari dermatology lab and biologically inspired machine-learning research in the STAIR Lab, both at Stanford University. He also conducted research at Johns Hopkins’ Thakor Lab studying methods to make smart prosthetics more reliable and easier to use. In 2011, he formed an undergraduate engineering team that designed a 3D skin imager to allow for efficient skin monitoring. Elliot led the team to a 1st place finish in the Collegiate Inventors Competition and served as lead author on a 3D teledermatology patent. Since co-founding 3Derm Systems in 2012, Elliot has served as CTO, architecting and developing a scalable, high-security platform for the transmission of dermatology images, as well as overseeing the development of the next generation 3D imager. In 2014, he was asked to give the token telemedicine talk at TEDMED.

20150817, Monday, August 17, 2015, Boston, MA, USA; CoPatient staff portraits and head shots at their current offices inside WeWork Boston on Monday August 17, 2015. ( lightchaser photography © 2015 )

CoPatient welcomed Tom Torre aboard as the team’s CEO in September of 2015. Tom has broad expertise in healthcare and financial services, with prior roles as the Senior Vice President and General Manager of Healthcare Payment Solutions at FIS Global before co-founding Alegeus Technologies in 2012. Tom graduated from Stevens Institute of Technology with a Bachelor of Science in Systems Planning and Management. He lives in Cape Elizabeth, Maine, with his wife and two daughters.


Professor Joglekar is an expert in design thinking, startup operations and technology management. Prior to his academic career, he worked in the technology sector and founded a software startup. Current projects address development of solar cleaning technology, management of technology readiness and risks, and analytics tools and processes that enhance patient engagement.

Panel Discussions

Guests will have the opportunity to choose from a series of panels. Please note: due to maximum room capacity, some panels may fill up. We will make every attempt to guarantee you can attend your preferred event!



With nearly 20 years of experience in the healthcare industry, Jim is a trusted adviser to provider organizations looking to improve government and commercial payor reimbursement, enhance revenues, and thrive in a value-based environment. As a member of ECG’s Contracting and Reimbursement practice, Jim has conducted dozens of consulting engagements focusing on managed care contracting, innovative and conventional reimbursement strategies, business operations, and strategic planning. He works closely with hospital and physician leaders to evaluate and execute strategies to project and improve upon their organizations’ financial performance, and they trust him to lead their most sensitive negotiations for medical group and hospital agreements. As the healthcare industry shifts toward value-based delivery systems, Jim’s clients rely on his knowledge of evolving payment arrangements such as bundled payments and shared savings, as well as his expertise in assessing the feasibility of developing and implementing clinically integrated provider networks.


Jon Kingsdale joined Wakely Consulting Group’s Boston office in 2010, bringing his extensive experience in health care exchanges to the company.

A frequent author and contributor to healthcare publications, Dr. Kingsdale is widely sought on both the state and national stage for his healthcare reform insights and public policy guidance. He was the founding Executive Director of the Commonwealth Health Insurance Connector Authority, an independent state agency established in 2006 under Massachusetts’ landmark health reform legislation. As the Executive Director for the country’s inaugural health benefit exchange, he led key initiatives to make health insurance universally available and to reform healthcare financing in Massachusetts.

As a senior executive at Tufts Health Plan for 20 years, Jon was responsible for strategic planning, product development, public affairs and government relations. Prior to Tufts Health Plan, he worked in strategic planning and reimbursement at Blue Cross Blue Shield of Massachusetts, researched hospital finances at the Harvard School of Public Health, consulted on health policy issues in Washington, D.C., and worked as a reporter for Forbes Magazine.


Mr. Kirk has over twenty years of experience in client management, project delivery, consulting, practice development and business operations. His health industry clients include payers, integrated delivery systems, clinical carve outs and PBMs. He has significant experience in health plan strategy, operations, cross functional program management and delivery. Areas of strong domain expertise include process improvement, member experience, campaign and channel management, network adequacy, provider contracting, clinical carve outs and vendor integration. Prior to joining Cognizant, Mr. Kirk was an Associate Director in Optum’s Payer Consulting Practice, a Manager with Pricewaterhouse Cooper’s Finance Advisory Practice, Senior Data Analyst with Aetna and a finance and operations leader with a regional pharmaceutical distributor.


Jane Maffie-Lee, MSN, FNP-BC is a Family Nurse Practitioner and the Clinical Program Director of the Ambulatory Practice of the Future. She joined this practice after 23 years as the Chief Operating Officer and Family Nurse Practitioner at Manet Community Health Center located in Quincy and Hull, Massachusetts. Prior to that, Jane worked at Massachusetts General Hospital in the Ambulatory Care Department as the Medical Specialties Clinic Nurse, at Bunker Hill Community Health Center and various units in the White Building including her first nursing position as a new nurse in the MGH Burn Unit.

Jane completed her undergraduate education in nursing receiving her BSN from the University of Iowa. She attended Boston University, getting her MSN with a specialty in Community Health. She became a board certified Family Nurse Practitioner after receiving her Certificate of Advanced Practice from Simmons College.

Her outside interests include biking, quilting, reading and having time off when she can enjoy the company of her husband and three sons.


Andrew J. Sussman, M.D., is Executive Vice President and Associate Chief Medical Officer of CVS Health and President of MinuteClinic. MinuteClinic is the largest and fastest growing retail medical clinic provider in the United States with over 980 retail health care centers located in CVS/pharmacy stores across 31 states. MinuteClinic has provided medical care to more than 24 million patients.

Under Dr. Sussman’s leadership MinuteClinic has expanded its range of clinical services and formed strategic affiliations with over 50 leading health care systems to improve patients’ access to high-quality medical treatment. Since 2011, MinuteClinic has added more than 500 new clinics and has announced plans to open an additional 500 clinics by 2017 with a target of a total of 1,500 clinics.

Prior to joining MinuteClinic in 2009, Dr. Sussman was Executive Vice President, Chief Operating Officer of UMass Memorial Medical Center, and an Associate Professor of Medicine at UMass Medical School in Worcester, MA. He was responsible for all clinical services and daily operations at UMass Memorial, an 800-bed academic medical center, the major teaching affiliate of UMass Medical School.

Before joining UMass Memorial in 2004, Dr. Sussman served as Chief Medical Officer of the Brigham and Women’s Physicians Organization, a multi-specialty academic physician practice composed of 800 Harvard Medical School faculty members practicing at Brigham and Women’s Hospital in Boston, MA. He was an Assistant Professor of Medicine at Harvard Medical School and practiced primary care internal medicine at Brigham and Women’s Hospital.

Dr. Sussman is a graduate of Harvard College and Harvard Medical School as well as Boston University School of Management. He has published work on health systems, quality improvement, medical management, and health care finance. He has been listed among America’s Best Doctors and Modern Healthcare’s 100 most influential people in health care.


Ned Rimer is the Faculty Director of the Health Sector Management Program at Boston University Questrom School of Business, where he also serves as a Lecturer and Executive in Residence. He has been an educator and entrepreneur for over thirty years. He was the Founder and Executive Director of Chronic Care Community Corps, a healthcare reform initiative that prepares and mobilizes the community to support those caring for others with serious illness. Rimer was also the Co-Founder and CEO of an innovative palliative care company that offers planning, coordination, and care continuity for individuals with life-threatening or life-altering conditions. Rimer has his MBA from the Questrom School of Business and his M.Ed from Harvard University.

Healthcare Quality


Evan Grossman is athenahealth’s Vice President of Client Performance, responsible for provider and practice optimization. Prior to his current role, Evan served as vice president, consulting responsible for athena’s consulting organization and vice president, product strategy, responsible for the athenaClinicals Electronic Health Record service.

Evan joined athenahealth in 2010 after serving in senior management positions at several technology-based companies, most recently as managing director, EMEA Retail, for RedPrairie Corp. He has also been a consultant with McKinsey & Co. and a journalist with PC Week. He obtained a bachelor’s degree from Harvard University.


Dr. Rosenblatt is a senior staff surgeon, surgical intensivists, Director of the Trauma Service at the Lahey Hospital and Medical Center in Burlington, Massachusetts, the tertiary care facility of Lahey Health System. He joined the staff in 1993. He holds a BA from Wesleyan University, his MD from Jefferson Medical College and his MPH and MBA from Boston University. He is a Clinical Associate Professor of Surgery at Tufts University School of Medicine. He has served as the Chief Medical Officer of the Lahey Hospital since July 2011. He has a deep and personal commitment to patient safety and has spoken nationally and internationally on Lahey’s use of the high reliability organization model in shaping its approach. In addition to his clinical, administrative and teaching responsibilities, Dr. Rosenblatt served 10 years as an Examiner with the Baldrige National Quality Program of the U.S. Department of Commerce, including a three-year appointment as one of the 12 members of the Judges Panel for the Baldrige Award.


Karla Schnell, RN, BN, is the National Healthcare Practice Clinical Lead at Centric Consulting, and is responsible for developing Centric’s National Healthcare Clinical Practice strategies and service offerings while leading and delivering all healthcare projects nationwide. Karla has spent more than 25 years deeply engaged in the Healthcare industry in Clinical practice, as a Health System Executive, IT and Clinical Informatics Professional and Consultant. Staying close to her roots as a clinician, Karla works to drive change management initiatives and to implement healthcare information technology to enable the process of care leading to true organizational transformation. Her specific expertise includes clinical and operational thought leadership, strategy development including the use of technology, PCMH and ACO design and execution, healthcare facility design to support operational process, physician and clinician adoption strategies, change management, process improvement, EHR design and implementation, project and program management.

Before joining Centric Consulting, Karla’s previous roles include Vice President of Provider Practice for FluidEdge Consulting, Senior Director of Clinical Informatics of LifePoint Hospitals and Director of Healthcare Practices for Navigant Consulting.


Junaid M. Sheikh, MBBS, is Director of Quality Improvement at Mount Auburn Cambridge Independent Practice Association (MACIPA). Junaid has a vast experience working in the Healthcare Industry of US and Pakistan in multiple roles ranging from practicing medicine to managing multi-disciplinary teams. He attained his medical degree (MBBS) from King Edward Medical University in Lahore, Pakistan and completed his MBA in Health Sector Management from Boston University. Junaid is interested in the strategy and operations aspects of successful healthcare systems and how these systems use big data to improve quality, efficiency, and profitability.


Joseph Restuccia, DrPH, MPH is Professor of Health Care and Operations Management and Dean’s Research Fellow in the BU School of Management’s Department of Operations and Technology Management. He also holds the positions of Research Scientist at the Veterans Health Administration’s Center for Organization, Leadership and Management Research and Visiting Professor at Bocconi University School of Management in Milan, Italy.

Dr. Restuccia’s teaching and research spans over 35 years and has focused on issues related to health care quality measurement and improvement, cost containment, information technology, system transformation, and evaluation of interventions intended to improve effectiveness of health care delivery. As well as Boston University School of Management, Restuccia has taught at BU’s School of Public Health, Bocconi University, University of Michigan, and University of California, Berkeley.

He is co-developer of the Appropriateness Evaluation Protocol (AEP), a method to evaluate appropriateness of hospitalization that has been the basis of numerous research studies as well as operational quality improvement programs throughout the world. Dr. Restuccia is currently co-principal investigator of a study of the impact of organizational factors on cost and quality of inpatient medical services at VHA’s 129 medical centers, an investigator on three studies involving hospital readmissions: one to identify potentially preventable readmissions, a second investigating leadership and other factors impact on reducing readmission rates, and a third to test a method of reducing readmission.

In the past, Dr. Restuccia has led studies supported by the Agency for Healthcare Research and Quality, the Commonwealth Fund, and the Robert Wood Johnson Foundation, among other funding organizations. He earned his doctoral degree in social and administrative health sciences and master’s degrees in health services management at the University of California, Berkeley and his bachelor’s degree at Tufts University. Between his studies at Tufts and Berkeley, Restuccia spent three years as a hospital manager.

Devices and Diagnostics


Jacques joined Analogic in 2014. Prior to that he was CEO of the company he founded, Coumans Care LLC, a thought leader and provider of patient-centric suites. Before that he was CMO of GE Healthcare’s Global Magnetic Resonance business. He also held the position of CMO of Philips Global Magnetic Resonance Business. Jacques is a physicist by training. He received his PhD from Carola-Wilhelmina University in Braunschweig, Germany, and an MSc degree from Eindhoven University of Technology, the Netherlands.


David N. Fisher is an industry expert in healthcare policy, reimbursement models, and advocacy in Washington, D.C. As Head of Global Policy and Government Affairs for Siemens Healthcare, he and histeam are responsible for understanding, educating, and advocating for how healthcare policy is changing the market and how these changes impact patients, providers, payers, and the industry.

Prior to joining Siemens in February 2012, Dave was Executive Director of the Medical Imaging and Technology Alliance (MITA), the leading industry association of medical imaging, radiation therapy and radiopharmaceutical manufacturers. Under Dave’s leadership the association led industry efforts to understand implications of Medicare imaging reimbursement changes; represented imaging manufacturers in negotiations with FDA on the Medical Device User Fee Act; and worked with CT manufacturers to develop the Dose Check Initiative, a proactive effort to address concerns about radiation dose. In addition, in his role as Executive Director of MITA Dave served as the Chairman of DITTA, the global association of imaging manufacturers.

Prior to joining MITA, Dave spent 13 years working on healthcare policy and financing issues in Congress and in the Executive branch including senior positions in the Senate and at the Office of Management and Budget.

Dave holds a Master of Public Policy and a Bachelor of Arts from Georgetown University. He lives in Washington, DC with his wife and daughters.


Kevin is Chief Executive Officer and Executive Chairman of Quanterix. In addition, he serves on the boards of several other technology companies focused on transforming the practices medicine and healthcare. Prior to Quanterix, he was President of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences (now PerkinElmer); and CEO of Zymark Corporation. Earlier Hrusovsky was President of FMC Pharmaceuticals and International Agricultural Products and held numerous management positions at DuPont. Hrusovsky currently serves on the Board of Directors of Quanterix, 908 Devices, SynapDx and Solect Energy. He also serves on Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. He formerly served on the boards of SeraCare (now Linden Partners), Caliper Life Sciences (now PKI), Xenogen – XGEN (now PKI) and Alliant Medical Technology. Kevin received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University. He is the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions in life sciences and personal medicine.


Dr. Ladin has over 20 years of management experience in the medical industry, government and academia, focusing on clinical applications, regulatory affairs and reimbursement strategies. His experience includes establishing reimbursement and regulatory strategies for therapeutic and diagnostic medical device companies, submission of regulatory applications, including 510(k) and PMAs for products in Class I-III and drug-device combination products. Dr. Ladin represented companies in negotiations with the FDA, European and Asian regulatory agencies, and served for five years as a scientific advisor to the Food and Drug Administration. Dr. Ladin, a recipient of the Whitaker Fellowship and International Research Awards, taught mechanical and biomedical engineering at MIT and Boston University. B.Sc., Aeronautical Engineering and M.Sc., Biomedical Engineering, both from the Technion, Israel Institute of Technology; Ph.D., Medical Engineering, MIT-Harvard Medical School / Division of Health Science and Technology.


Ivan S. Salgo, MD, MS, MBA is Associate Chief Medical Officer for Philips Patient Care and Monitoring Solutions (PCMS). In his role, he is involved in medical device technology strategy and linking those to business new models. He is part of an innovations team that focuses on leading broad-based medical, science and technology areas to bring clinically meaningful innovation to the bedside. Prior to joining PCMS, Ivan helped in several roles at Philips Ultrasound bringing echo innovations to clinical practice. This included serving as R&D lead for signal & image processing groups that developed diagnostic solutions for structural heart disease and heart failure. In 2007, this culminated in 3DTEE being launched and adopted to be standard of care for mitral valve repair. Ivan also served as leader for the Global Cardiology Segment for the platform launch of EPIQ 7C in 2013 and Affiniti 70 in 2014, which are Philips flagship echocardiography ultrasound systems.

He has been co-investigator of an NIH Biomedical Research Partnership from 2003 to 2013 on Cardiac Surgical Image Guided Intervention and Pediatric Aortic Valve Repair from 2011 to 2016 with Boston Children’s Hospital/Harvard Medical School. Prior to joining Philips, he was director of the Intraoperative Echocardiography Program and worked as a cardiac anesthesiologist and cardiac surgery intensivist at the University of Pennsylvania.

Ivan received his B.S. and M.S. degrees from Columbia University School of Engineering. He received his M.D. degree with Distinction in Research from the Mount Sinai School of Medicine in New York City. He did his residency and fellowship at the University of Pennsylvania in Cardiothoracic Anesthesiology where he later joined the faculty. He also received his M.B.A. degree from the Massachusetts Institute of Technology Sloan School of Management in 2012.


Andrea Sodano, Ph.D. has held executive positions at IBM, Symmetrix, the Hay Group and Wal-Mart. Her primary focus has been business transformation, consulting, and organization change. She also was a senior consultant and adjunct faculty at Dartmouth Medical School. She holds a Ph.D. from the University of Massachusetts in Clinical and Organization Psychology. She was a predoctoral intern at Yale Medical School and held a postdoctoral fellowship at Harvard Medical School. She is a member of the Boston Club and holds Board positions with the William James College and Eastman. She currently is the Faculty Director of the Health Sector Management Internship Program and the Dean’s Health and Life Sciences Fellows Program.

Pharma / Biotech


Mark is Vice President, Product Strategy Team Leader, Angioedema within the Shire Rare Disease Business Unit, based in Lexington, MA. Originally from the UK, he has over 25 years’ commercial and franchise leadership experience within global healthcare organizations, living for the last 18 years in the US. He has successfully built teams and delivered results for global and US companies in Pharmaceutical, Biotechnology and Medical Device spaces in both pre- and post-launch environments. Before joining Shire in June 2009, Mark had held positions of increasing seniority within GSK, AstraZeneca, Johnson and Johnson and Endo Pharmaceuticals, where, as Vice President of Marketing, he was responsible for a $1bn portfolio of products. When not working, Mark enjoys keeping fit and running around after his three children. Not unrelatedly, he also enjoys climbing into caves, jumping from airplanes, playing rugby and riding dangerous motorcycles.


Erika Gill is a Senior Director in Program Leadership and Management at Biogen. Erika has responsibility for overseeing launch readiness and in-going success of a new product. During her 11+ years at Biogen, she has held several positions including Senior Director of Nursing Operations, Director of Commercial Operations (Meeting Planning, Strategic Sourcing, and Field Ops), Director of Franchise Marketing, Chief of Staff, and Director of Patient Services. Prior to Biogen, Erika was a Senior Reimbursement Manager at Genzyme, and held several management roles at Brigham & Women’s Hospital. Erika has an MBA from Boston University, and undergrad in Health Management & Policy from University of New Hampshire. Erika is passionate about designing care, services and products to best support patients.


Jeff Pfefferkorn is Executive Director for Pfizer’s Cardiovascular, Metabolic & Endocrine Disease Research Unit located in Cambridge, MA. He is a scientific leader with integrated drug discovery experience from exploratory through early clinical development. Jeff currently leads portfolio strategy for the research unit and is also the interim head of the liver metabolism group focused on therapeutic approaches for Type 2 diabetes as well as NAFLD/NASH. Jeff completed his B.S. in chemistry at Case Western Reserve University and his Ph.D. in organic chemistry at the Scripps Research Institute after which he joined Pfizer in 2001.


Dr. Safia Khalil Rizvi is the President of Rediscovery Life sciences a company dedicated to addressing the unmet need in severe disease thru unique technology that enables matching disease pathways with existing drugs mechanism of action. Ms Rizvi has lived and worked in the US, Europe and Asia and has extensive experience across the value chain of Pharmaceutical and Biotech Industry; from Research and Development to commercialization of small molecules and biologics in the US, Europe and Asia.

Prior to this role she was GM/VP of Galderma’s Pharmaceutical business in the US and managed all aspect of ~700 Million business. She had also served as Managing Director/ GM of India for UCB Pharmaceutical and member of the UCB’s Asia pacific leadership team for several years,
Before joining UCB she worked at Medlmmune as Senior Director, International Marketing where she was responsible for International Influenza and RSV business. Her entry in the Industry was via GlaxosmithKline, where she spent 9 years and had several role of increasing responsibility from R &D scientist to the Senior Director, Business Strategy and Marketing, Influenza Franchise. At GSK, she also served at the office of the CEO where she was responsible for benchmarking and measuring business excellence and performance globally as well as assisting the CEO and Corporate Executive Team with strategic projects to drive growth and/or improve effectiveness.

Safia Rizvi is a graduate of Wharton School of Business where she received her MBA in Health Care Management. She also holds a Ph.D. in Chemistry and Biochemistry. She is the author of numerous published articles in peer-reviewed scientific journals. During her science days she was affiliated with the Department of Bioinformatics in R &D at GlaxoSmithKline, where the focus of her work was the impact of genomic information on drug discovery. She identified numerous novel genes sequences for biotherapeutics and drug targets for cancer treatment from human genome data and is an inventor on dozens of gene sequence patents in the US and Europe. Before joining Industry, Dr. Rizvi worked as a member of the Research Faculty at the University of Pennsylvania, School of Medicine, where focus of her research was structural biology/protein structure with the disease focused inflammation, cardiovascular disease and cystic fibrosis.

For last 15 years Safia Rizvi has also been deeply involved in the empowerment of economically challenged women through access to education. She is the founder of eLIT — empowerment through Learning Information Technology (https://www.elitonline.org/).
eLIT is a global, not-for-profit initiative dedicated to providing information access and computer literacy for economically disadvantaged women and children.
Among her awards are the “Altrusa Club International Women Award “, fellowship from the American Heart Association, American Red Cross Spectrum “Rising Star 2001 Award”, “National Working Mother of the Year 2001” Award and “Women of Distinction 2005” Award and Who is Who of Distinguished Alumni.

She is voracious reader and equally voracious eater and enjoys cooking and yoga regularly.


Mark Philip has over 25 years experience in the Biopharma, Medical Device and Diagnostic industries, operating in Europe, the USA and Asia. As CEO, president or board member of multiple start-ups, medium size and large businesses, Mark has orchestrated multiple turnarounds, built product pipelines, launched new products, sold companies and created significant shareholder value.

Mark is currently a consultant to the industry advising on acquisitions, product development, commercial strategies and fund raising for a variety of small and large, private and public companies. He is also the Chief Operating Officer of Portal Instruments, Inc.

Mark has a bachelor’s degree in Biochemistry and a PhD in Stem Cell Research from Trent Polytechnic, Nottingham, UK, and was the Leukemia Research Fund Postdoctoral Research Fellow at Nottingham University. Mark also has an MBA from Lake Forest Graduate School of Management in Chicago.

Personalized Medicine


Dr. Funke received her Ph.D. in molecular genetics from the University of Würzburg, Germany and trained as a postdoctoral fellow at the Albert Einstein College of Medicine in New York where she identified the gene for 22q11 deletion syndrome. She continued her research on 22q11DS at Harvard Medical School where she also trained in Clinical Molecular Genetics. Dr. Funke obtained her ABMG Board certification in 2007 and is now Director of Clinical Research and Development at the Laboratory for Molecular Medicine (LMM) and Associate Professor of Pathology at Harvard Medical School. She also oversees clinical genetic testing and signout for inherited cardiovascular disorders and implemented clinical next generation sequencing (NGS) for these disorders. The LMM was one of the first laboratories in the US to offer clinical NGS and continues to be on the forefront of medical genomics and personalized genetic medicine. Dr. Funke’s current efforts focus on developing standards for gene and variant curation, clinical whole exome sequencing and on developing approaches to promote the adoption of preemptive genetic medicine.


Dr. Morosini, an MD Pathologist, who also has a Master’s Degree in Social Work, is a voice for cancer patients and strong supporter of stem cell research. She currently serves as Vice President of Clinical Development and Lead Patient Advocate at Foundation Medicine.

Dr. Morosini was inspired by the philanthropic efforts of her sister Dana Reeve, a non-smoker who died from lung cancer and her brother-in-law Christopher Reeve, the late actor who played Superman, who had a passion for stem cell research for spinal cord injuries and other illnesses. After seeing their admirable work, Morosini incorporated medical and philanthropic synergies in her career, spending the past 10 years as a biotech and pharmaceutical professional, and becoming a noted, inspirational speaker to families dealing with medical hardships. Dr. Morosini sits on the Boards of the National Comprehensive Cancer Network Foundation and National Cancer Institute’s Director’s Consumer Liaison Group providing strategic guidance and advice on public health and policy matters.

In addition, Morosini has also contributed to the development of a data element taxonomy of disease models for use by genomic researchers as part of the federal government’s National Institute of Standards and Technology Advanced Technology Program, which is responsible for developing precise and standardized ways of measuring emerging science and technologies.

Dr. Morosini received her medical degree from Boston University School Medicine and completed a pathology residency at Boston Medical Center. She received her MSW from NYU, and her BA in English from Mount Holyoke College.


Dr. Rollins received his undergraduate degree from Amherst College, and his MD and PhD from Case Western Reserve University. He completed internship and residency training in Internal Medicine at Beth Israel Hospital, Boston, and a fellowship in Medical Oncology at Dana-Farber Cancer Institute. Dr. Rollins has been a member of the faculty at Dana-Farber since 1989. His research examines the effects of inflammation on cancer with a recent emphasis on the genetic alterations associated with childhood histiocytic diseases. As Chief Scientific Officer at Dana-Farber, Dr. Rollins has helped lead a project designed to obtain broad genomic profiles on all patients who come to the Institute for cancer care.


Birgit Schoeberl, Ph.D. has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009 to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational models of signaling networks. Dr. Schoeberl holds a Ph.D. in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an M.S. in chemical engineering from the University of Karlsruhe in Germany.


Rachel Sha is Senior Director of Strategy & Business Development for Integrated Care at Sanofi. She is focused on external opportunities in patient-centric connected health solutions that enable richer understanding of a patient’s condition and real time management of chronic diseases to improve overall patient experience, clinical outcomes, and reduce cost of care. In addition, she is engaged in Sanofi Corporate Strategy initiatives and is the alliance manager for the Sanofi Google collaboration.

She joined Genzyme in 2005 and has held roles of increasing responsibility in Business Development and Corporate Development for Genzyme / Sanofi. She was the Head of Biosurgery Business Development where she led efforts to identify, evaluate, and negotiate licensing and M&A opportunities as well as work with leadership to set business strategy. She also spent two years as Head of Global Marketing & Strategy for Surgical Devices.

Before Sanofi / Genzyme, Rachel was a manager at Accenture. Her experience crossed a broad range of business issues from strategy to process to technology implementation in electronics & high tech, pharmaceutical, financial services, and media and entertainment industries.

Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.


Roberta N. Clarke, Associate Professor at Boston University’s School of Management, was one of the first experts in the field of health care marketing. Professor Clarke is the 1995 recipient of the American Marketing Association’s prestigious Philip Kotler Award for Excellence in Healthcare Marketing and was former President of the Society for Healthcare Planning and Marketing, a national professional society of 3500 members affiliated with the American Hospital Association. Dr. Clarke won the Health Care Marketer of the Year Award from the American College of Health Care Marketing in 1985, the first year it was awarded. With Philip Kotler, she co-authored Marketing for Health Care Organizations, considered to be the leading text in the field of health care marketing.

Professor Clarke began teaching health care marketing courses at Boston University’s Health Care Management Program in 1974 and in Boston University’s School of Medicine in 1981, positioning her as one of the first to specialize in the field. Dr. Clarke serves on the Editorial Review Boards of Health Services Management Research and Strategies for Healthcare Excellence, and formerly on the editorial review boards of the Journal of Health Care Marketing and Health Care Management Review. She has been the faculty director of the Boston University Biotechnology Association since its inception in 2002.

Professor Clarke received her MBA and Doctorate from the Harvard Graduate School of Business Administration. She is a recipient of the Boston University School of Management Broderick Prize for Excellence in Teaching. Her executive and graduate student audiences have wide ranging orientations, from health care and nonprofit to medical devices and biotechnology, and services.

Professor Clarke is a nationally known speaker and writer in the health/medical sector and in the area of service management. She has worked extensively with managed care organizations, medical group practices, hospitals, sub-acute and extended care facilities, community health centers, home health care providers, physician and clinical professional associations, as well as with medical device and instrumentation manufacturers, biotechnology and life science companies, both in the U.S. and abroad.

In addition, Professor Clarke is a board member and former vice chair of the Board of the New England Organ Bank, the federally designated organ procurement organization for New England. She was also the Vice Chair of the Board of the Academy for Educational Development, a human development agency with more than 4300 programs in 150+ countries, which is now part of FHI 360, a global development agency. In 2007, she co-founded Pediatric Weight Management Centers, a pediatric obesity service that operated in collaboration with the physicians of Children’s Hospital Boston and is currently the co-founder and president of the U.S. unit of Advance Medical, an independent, acute care medical review service which serves over 1.5 million people for second medical opinions